Immuno-Oncology 360° Community News

Dr Adrelia Allen, Merck, will moderate a panel discussion on strategies for equitable enrollment in oncology and cancer immunotherapy trials. This panel will discuss actionable strategies for overcoming barriers to participation in oncology and immuno-oncology trials, emphasizing operational and community-based solutions. Panelists include: ? Brittany Gerald-Lewis, Moderna ? Julie Martin, Scimega | Expert Oncology CRO ? Jeanne Regnante, Patient 3i / Tigerlily Foundation ?? Learn more at IO360Summit.com #IO360Summit

Dr Richard Walovitch, VOIANT?, will present a Central Review of Immuno-Oncology Efficacy Data: Current Status and Future Developments at the #IO360Summit This talk will cover: ? Modification of RECIST criteria to address pseudo progression and intralesional treatment ? Role of a central oncology review after central radiology review ? How an AI powered automated workflow can facilitate a complex multistep central review process ? How AI will change assessment paradigms in the near future ?? Learn more at IO360Summit.com

Dr Raulca Verona, AbbVie, will highlight the innovative design of Etentamig (ABBV-383), a BCMA x CD3 bispecific T-cell engager with enhanced tumor targeting and optimized T-cell engagement at the upcoming IO360° Summit. More specifically she will cover: - Clinical insights from Etentamig’s first-in-human phase 1 trial - High-avidity BCMA binding to maximize tumor targeting and counteract soluble BCMA (sBCMA) - Low-affinity CD3 engagement to reduce cytokine production, retain tumor cell cytotoxicity, and prevent T-cell exhaustion ?? Learn more at IO360Summit.com #IO360Summit

Hear from Bicara Therapeutics' Dr Rachel Salazar on how IO360o showcases all perspectives within immuno-oncology. ?? Learn more at IO360Summit.com #IO360Summit #Conference

Dr Gideon Blumenthal, Merck Research Labs, will moderate a panel discussion on "Navigating Project Optimus: Balancing Innovation and Practicality in IO Dose Selection" at the 11th Annual IO360o Summit. This session will examine how Project Optimus is transforming dose selection in IO trials, moving beyond the traditional maximum tolerated dose (MTD) to identify the optimal dose that maximizes efficacy while maintaining an acceptable safety profile. Panelists will discuss the nuanced requirements for dose-response analysis, including FDA’s expectation for efficacy assessments before reaching MTD, along with strategies to navigate these challenges in trial design and resource allocation. Panelists include: ? Andrea Ferris, LUNGevity Foundation ? Dr Greg Goldmacher, Merck Research Labs ? Dr Ryan Sullivan, Massachusetts General Hospital / Harvard Medical School ? Dr Wim Vos, radiomics.bio ?? Learn more at IO360Summit.com #IO360Summit #immunooncology

Hear from Bristol Myers Squibb's former SVP, Dr Kristen Hege, as she shares what she enjoys most about the IO360°?Summit. ?? Learn more at IO360Summit.com #IO360Summit #ImmunoOncology #Conference

Our team is looking forward to #IO360 next month. Hope to see you there!

Carol Haddad, Merck, will moderate a panel discussion on "Navigating the Shifting Landscape of Trial Placement and Site Selection for Global Oncology Research" at the 11th Annual IO360° Summit. Key Topics Include: ? Adapting to geopolitical factors for successful global collaborations ? Initiatives to expand trials into Africa, the Middle East, and Latin America to enhance representation and foster inclusive findings ? Identifying potential opportunities for future trial placements, considering emerging healthcare infrastructure, regulatory environments, patient populations, and collaboration opportunities with local stakeholders Panelists include: ? Dr Andy Kinley, Precision For Medicine ? Nathanial "Nat" Ramuthaga, Roche ? Millie Shultz, Pfizer ? Sarah White, Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center) ?? Learn more at IO360Summit.com #IO360Summit

Dr Theresa LaVallee, Chief Development Officer of Coherus BioSciences, recently shepherded their drug toripalimab through a challenging approval process. She tells us what is next for the drug, the challenges facing medicine developers, and what keeps her enthusiastic about immuno-oncology. ?? Read the interview here: https://lnkd.in/eb-ty6dn #IO360Summit

Dr Charles Drake, Johnson & Johnson Innovative Medicine, will present on Solid Tumor CD3 Redirectors at the 11th Annual Immuno-Oncology 360o Summit. ?? Learn more at IO360Summit.com #IO360Summit